Catalyst Pharmaceuticals Inc. Watch

from 10-Q 42 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Both (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Text Omitted From This Exhibit Is Marked With [***] License, Supply and Commercialization Agreement

from 10-K 5 pages Catalyst Pharmaceuticals, Inc. Executive Severance and Change in Control Plan Effective: February 22, 2018 Amended: May 24, 2018 Further Amended: November 16, 2023

from 10-K 11 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Separation Agreement and General Release

from 10-K 9 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Separation Agreement and General Release

from 10-K 3 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted

from 10-K 3 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted

from 10-Q 5 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Amendment to Transition Services Agreement

from 8-K 4 pages Amendment to the Investment Agreement Between Santhera Pharmaceuticals Holding AG and Catalyst Pharmaceuticals, Inc. Whereas A. as of June 19, 2023, the Parties Entered Into an Investment Agreement (The Investment Agreement) Regarding the Private Placement of 14,146,882 Pre-Reverse Split Treasury Shares of the Company With the Investor. B. the Parties Wish to Amend the Investment Agreement by Way of This Amendment Agreement (The Amendment Agreement). Now, Therefore, the Parties Agree as Follows: 1. Unless Otherwise Defined in This Amendment Agreement, Capitalized Terms Used Herein Shall Have the Meanings Ascribed to Them in the Investment Agreement. 2. the Parties Agree That Article 5.2(b) of the Investment Agreement Shall Be Deleted in Its Entirety Without Replacement. 3. Save as Varied by This Amendment Agreement, All Terms and Conditions of the Investment Agreement Shall Remain in Full Force and Effect as Set Forth Therein. 4. Article 7 (General Provisions) of the Investment Agreement Shall Apply Mutatis Mutandis to This Amendment Agreement. 5. This Amendment Agreement Shall Be Exclusively Governed by and Construed in Accordance With the Substantive Laws of Switzerland, Excluding Its Conflict of Laws Principles. 6. Disputes Under This Amendment Agreement Shall Be Resolved by Binding Arbitration Conducted in the Manner and at the Place Set Forth in the Applicable Provision of the License and Collaboration Agreement

from 8-K 18 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted

from 8-K 54 pages License and Collaboration Agreement

from 8-K 34 pages Exhibit H Form of Supply Agreement Supply Agreement Between Eisai Co., Ltd. and Catalyst Pharmaceuticals, Inc. Dated as of [ • ], 2022

from 8-K 40 pages Exhibit J Form of Transition Services Agreement Transition Services Agreement by and Between Eisai Inc. and Catalyst Pharmaceuticals, Inc. Dated as of [•]

from 8-K 2 pages Eighth Amendment to Employment Agreement

from 8-K 60 pages License and Asset Purchase Agreement

from 8-K 11 pages Settlement Agreement

from 8-K 38 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Both (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Text Omitted From This Exhibit Is Marked With [***] License and Supply Agreement Catalyst Pharmaceuticals, Inc. - And - Dydo Pharma, Inc. Dated as Of: June 28, 2021

from 8-K 2 pages Seventh Amendment to Employment Agreement

from 8-K 33 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Both (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Text Omitted From This Exhibit Is Marked With [***] License & Supply Agreement Kye Pharmaceuticals Inc. - And - Catalyst Pharmaceuticals, Inc Dated as Of: 14 August 2020

from 8-K 16 pages Fifth Amendment to Lease

from 8-K 8 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Such Information Has Been Marked Herein With [***] Amendment No. 2 to License Agreement